Regulatory Discussions Ongoing; Drisapersen Re-Dosing to Start in Q3 LEIDEN, The Netherlands, May 20, 2014 (GLOBE NEWSWIRE) — Prosensa Holding N.V. (Nasdaq:RNA), the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, today reported financial results for the first quarter ending March 31, 2014 and provided an update on the… Continue reading Prosensa Announces 1st Quarter 2014 Financial Results and Recent Corporate Developments
Blog posts
Prosensa Provides Update on Drisapersen
Re-dosing plans are underway and 96-week data from an open-label extension study of drisapersen for the treatment of DMD presented at the American Academy of Neurology (AAN) Leiden, The Netherlands, May 1, 2014 (GLOBE NEWSWIRE) — Prosensa Holding N.V. (NASDAQ: RNA) the Dutch biopharmaceutical company focusing on rare diseases with a high unmet medical need,… Continue reading Prosensa Provides Update on Drisapersen
MUCOSIS ANNOUNCES A STRATEGIC PARTNERSHIP WITH CHANGCHUN BCHT BIOTECHNOLOGY OF CHINA AND RAISES ADDITIONAL CAPITAL
Groningen, the Netherlands, April 15, 2014 — Biotechnology company Mucosis B.V. today announced that it entered into a long-term collaboration and license agreement with China-based Changchun BCHT Biotechnology Co (BCHT) and raised EUR 5 million, in a new financing round. Under the agreement with BCHT, Mucosis will receive an equity investment along with customary payments… Continue reading MUCOSIS ANNOUNCES A STRATEGIC PARTNERSHIP WITH CHANGCHUN BCHT BIOTECHNOLOGY OF CHINA AND RAISES ADDITIONAL CAPITAL
Prosensa to Appoint Michael Wyzga to Supervisory Board
Leiden, The Netherlands, April 8, 2014 (GLOBE NEWSWIRE) — Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical company focusing on rare diseases with a high unmet medical need, today announced that Michael S. Wyzga has been nominated for appointment to its Supervisory Board at the next shareholders’ meeting, scheduled for June 17, 2014. “We welcome… Continue reading Prosensa to Appoint Michael Wyzga to Supervisory Board
Kiadis Pharma organizes a Satellite Symposium on March 30, 2014 at the 40th Annual Meeting of the European Society for Blood and Marrow Transplantation
Amsterdam, The Netherlands, March 24, 2014 – Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing T-cell immunotherapy treatments for blood cancers, today announces that it will organize a satellite symposium on March 30, 2014 at the 40th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Milan, Italy.
